Literature DB >> 16046589

Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells.

Takehisa Kawata1, Yasuo Imanishi, Keisuke Kobayashi, Naoyoshi Onoda, Yoshiaki Takemoto, Hideki Tahara, Senji Okuno, Eiji Ishimura, Takami Miki, Tetsuro Ishikawa, Masaaki Inaba, Yoshiki Nishizawa.   

Abstract

CONTEXT: Although serum calcium (Ca2+) concentration regulates the generation of amino-terminally (N-terminally) truncated forms of human PTH (hPTH) degraded from (1-84)hPTH, no studies have yet reported whether the parathyroid gland itself is responsible for this process.
OBJECTIVE: Our objective was to determine the site of N-terminal truncation and its roles in PTH metabolism in parathyroid cells in vitro.
METHODS: The effect of extracellular Ca2+ concentration was examined on N-terminal truncation in primary cultured parathyroid cells. The parathyroid glands were obtained from the patients with primary and uremia-associated secondary hyperparathyroidisms who underwent therapeutic parathyroidectomies.
RESULTS: The N-terminally truncated fragments were detectable with commercially available intact PTH (I-PTH) assays, but not with the bio-intact PTH (Bio-PTH) assay, which detected only the (1-84)hPTH. HPLC revealed that generation of N-terminally truncated fragments detectable by I-PTH increased with extracellular Ca2+ concentration. Suppression of PTH secretion by increasing the extracellular Ca2+ concentration was more evident with the Bio-PTH assay than with the I-PTH assay for both cultured parathyroid cells prepared from parathyroid adenomas and uremia-associated secondary hyperparathyroidism. The Bio-PTH/I-PTH ratio, which is the ratio of (1-84)hPTH to the sum of (1-84)hPTH and N-terminally truncated fragments, decreased in response to increases in extracellular Ca2+.
CONCLUSIONS: These findings suggest that the N-terminal truncation is regulated by extracellular Ca2+ concentration and works to suppress the generation of (1-84)hPTH in parathyroid cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046589     DOI: 10.1210/jc.2005-0243

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Association of increased active PTH(1-84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D.

Authors:  M Kurajoh; M Inaba; S Yamada; Y Imanishi; T Tsuchida; E Ishimura; Y Nishizawa
Journal:  Osteoporos Int       Date:  2008-02-01       Impact factor: 4.507

2.  Increased active PTH(1-84) fraction as a predictor of poor mortality in male hemodialysis patients.

Authors:  M Inaba; S Okuno; Y Imanishi; E Ishimura; T Yamakawa; S Shoji
Journal:  Osteoporos Int       Date:  2013-09-13       Impact factor: 4.507

3.  Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.

Authors:  M Kurajoh; M Inaba; S Okuno; H Nagayama; S Yamada; Y Imanishi; E Ishimura; S Shoji; T Yamakawa; Y Nishizawa
Journal:  Osteoporos Int       Date:  2010-05-07       Impact factor: 4.507

4.  Amino terminal cleavage of PTH(1-84) to PTH(7-84) is regulated by serum calcium concentration via calcium-sensing receptor in hemodialysis patients.

Authors:  Masao Koshikawa; Kensuke Nishiguchi; Soshi Yorifuji; Keiji Shimazu; Koji Takaori; Keita Mori; Eriko Eguchi; Kikuo Okada; Atsuo Tanaka; Takashi Kuwahara
Journal:  Clin Exp Nephrol       Date:  2010-02-04       Impact factor: 2.801

5.  Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy.

Authors:  Ryo Koda; Junichiro James Kazama; Koji Matsuo; Kazuko Kawamura; Suguru Yamamoto; Minako Wakasugi; Tetsuro Takeda; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2014-11-11       Impact factor: 2.801

6.  Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium.

Authors:  Carmen Sánchez-González; Maria Luisa Gonzalez-Casaus; Víctor Lorenzo Sellares; Marta Albalate; José-Vicente Torregrosa; Sebastian Mas; Alberto Ortiz; Mariano Rodriguez; Emilio Gonzalez-Parra
Journal:  Front Physiol       Date:  2018-11-20       Impact factor: 4.566

7.  Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients.

Authors:  Fumihiko Koiwa; Shin Tokunaga; Shinji Asada; Yuichi Endo; Masafumi Fukagawa; Tadao Akizawa
Journal:  Kidney Int Rep       Date:  2021-08-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.